Back

Impact of taurolidine use during cardiac electronic implantable device implantation in heart failure patients

8 April 2024 (08:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session on devices, others Device Complications and Lead Extraction EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Alfonsomaria Salucci

University of Naples Federico II, Naples (Italy)

108 More presentations in this session

Presentation thumbnail
Emergency leadless pacing implantation is feasible and safe out-of-hours
Doctor F. O'Rourke (London, GB)
Abstract Slides Video
Presentation thumbnail
Outcomes of subcutaneous implantable cardioverter defibrillators: UK tertiary centre experience
Doctor L. Toon (Southampton, GB)
Abstract Slides Video
Presentation thumbnail
Evaluation of the quality of life of patients with leadless pacing system during 1 year follow-up period
Doctor A. Baimbetov (Almaty, KZ)
Abstract Slides
Presentation thumbnail
Which paced QRS duration can be achieved in selective and non-selective His bundle pacing?
Mr C. Israel (Bielefeld, DE)
Abstract Slides Video
Presentation thumbnail
Procedural heart rate variability and its effect on short-term symptoms after cardioneuromodulation procedure
Doctor S. AYGUN (Ankara, TR)
Abstract

Access the full session

Session thumbnail
Poster session on devices, others

The Event

Event poster

EHRA 2024

8 April 2024 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Tauropace reduces infections in patients with heart failure and reduced ejection fraction after cardiac electronic implantable device implantation.
thumbnail
Congress Presentation
Postoperative antibiotic prophylaxis following cardiac implantable electronic device implantation and the risk of device infection
thumbnail
Congress Presentation
Time to benefit of antibacterial envelope use to prevent cardiac implantable device infection: a meta-analysis of reconstructed individual patient data